Shreya Ghimire, Biyun Xue, Kun Li, Ryan M Gannon, et. al.doi: https://doi.org/10.1101/2024.07.03.60194 Abstract Treatments available to prevent progression of virus-induced lung diseases, including coronavirus disease 2019 (COVID-19) are of limited benefit once respiratory failure occurs. The efficacy of approved and emerging cytokine signaling-modulating antibodies is variable and is affected by disease course and patient-specific inflammation patterns. Therefore, understanding the role of inflammation on the […]